Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

34) Interest income 3 212 48 1,001 Interest expense (52) (183) (240) (640) Other income (expense), net -- (12) 10 26 --- --- --- --- Net loss $(6,756) $(6,313) $(16,789) $(21,247) ======= ======= ======== ======== Basic and diluted net loss per share $(0.38) $(0.36) $(0.95) $(1.21) ====== ====== ====== ====== Shares used to compute basic and diluted net loss per share 17,617,209 17,538,886 17,588,832 17,508,094 ========== ========== ========== ========== Non-cash stock-based compensation expense included in operating expenses: (1) Research and development $148 $183 $596 $597 (2) General and administrative 576 190 1,025 570 ---- ---- ------ ------ $724 $373 $1,621 $1,167 ==== ==== ====== ======
                           NEUROGESX, INC.
               Condensed Consolidated Balance Sheets
                           (in thousands)

                                               September 30,   December 31,
                                                   2009            2008
                                               -------------   ------------
                                                 (unaudited)        (1)
                                                 -----------        ---
                           Assets
     Current assets:
       Cash and cash equivalents                     $48,468        $10,435
       
'/>"/>
SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... NextCODE Health, which enables clinicians and researchers to ... today announced the launch of its new genomic data analysis ... American Society of Human Genetics (ASHG) annual meeting in ... and apply for free beta access, visit www.nextcode.com . ... be viewed here . The Exchange: ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Another Key Regulatory MilestoneLONDON, March 10 Monsanto,s historic ... and biotechnology has contributed to a 24 percent compound ... segment since 2001. This is one of the ... Commercial, will tell investors today as part of a ...
... has long been known for its world-record-breaking carbon ... have discovered new uses by spinning carbon nanotubes ... , Breakthroughs Without Broken Threads ... to grow carbon nanotubes of world-record breaking lengths, ...
... American Pacific Corporation (Nasdaq: APFC ) is ... Chemicals LLC (AFC), located near Sacramento California, recently inaugurated ... The new facility can accommodate either batch reactors (20 ... using up to 7 reactors from 0.25 to 1 ...
Cached Biology Technology:Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 2Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 3Spinning carbon nanotubes spawns new wireless applications 2AMPAC Fine Chemicals Announces the Inauguration of the New cGMP Continuous Processing Development Facility 2
(Date:10/18/2014)... In a sample of patients with undiagnosed, suspected genetic ... associated with a higher molecular diagnostic yield than traditional ... JAMA . The study is being released to ... meeting. , Exome sequencing, which sequences the protein­coding region ... genetic material present in a cell or organism), has ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
(Date:10/17/2014)... available in German . ... few drugs. When treating overdoses, doctors are often limited to ... if there is a combination of drugs involved. So what ... swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from the ... an answer to this question. "The task was to develop ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... (Santa Barbara, Calif.) Viruses fill the ocean ... marine microbiology, according to a professor of biology at ... Carlson, professor with UCSB,s Department of Ecology, Evolution, and ... of marine viruses published this week by the ...
... transport system inside living cells is a well-oiled machine with ... around the cell. These molecular motors are responsible for a ... on the go. They can put themselves into "energy save ... what gets moved around the cell, and when. ...
... is available in Spanish . A ... what is causing the decline in bumble bee populations and ... the next generation of greenhouse pollinators. Bumble bees, like ... used to pollinate greenhouse crops like peppers and tomatoes. But ...
Cached Biology News:Decade-long study reveals recurring patterns of viruses in the open ocean 2Decade-long study reveals recurring patterns of viruses in the open ocean 3Carnegie Mellon scientists discover how molecular motors go into 'energy save mode' 2Carnegie Mellon scientists discover how molecular motors go into 'energy save mode' 3The flight of the bumble bee: Why are they disappearing? 2
...
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
... Nuclease catalyzes the degradation of single-stranded DNA ... products. While the nuclease prefers ssDNA over ... the enzyme degrades double-stranded DNA from both ... used for transcript mapping studies (3,4), for ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: